argenex SE $ARGX Stock Holdings Lowered by Jennison Associates LLC

Jennison Associates LLC lessened its position in argenex SE (NASDAQ:ARGX) by 9.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 240,228 shares of the company’s stock after selling 24,419 shares during the period. Jennison Associates LLC’s holdings in argenex were worth $177,182,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ARGX. iA Global Asset Management Inc. increased its stake in shares of argenex by 10.3% in the third quarter. iA Global Asset Management Inc. now owns 6,010 shares of the company’s stock valued at $4,433,000 after purchasing an additional 560 shares during the period. Bailard Inc. acquired a new position in shares of argenex during the third quarter worth approximately $738,000. Wealth Enhancement Advisory Services LLC bought a new position in argenex in the 3rd quarter worth approximately $295,000. J.Safra Asset Management Corp increased its position in argenex by 53.3% in the 3rd quarter. J.Safra Asset Management Corp now owns 955 shares of the company’s stock valued at $704,000 after acquiring an additional 332 shares during the period. Finally, Sequoia Financial Advisors LLC raised its stake in argenex by 3.4% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 1,895 shares of the company’s stock valued at $1,398,000 after acquiring an additional 62 shares in the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

argenex Stock Down 1.5%

NASDAQ:ARGX opened at $814.74 on Friday. The stock has a fifty day simple moving average of $859.47 and a 200 day simple moving average of $771.27. The firm has a market capitalization of $50.42 billion, a price-to-earnings ratio of 34.98, a price-to-earnings-growth ratio of 0.53 and a beta of 0.38. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, October 30th. The company reported $4.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.37 by $0.03. argenex had a return on equity of 29.78% and a net margin of 41.58%.The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.07 billion. Equities analysts predict that argenex SE will post 3.13 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Wall Street Zen cut argenex from a “buy” rating to a “hold” rating in a research note on Saturday, January 10th. HC Wainwright increased their target price on shares of argenex from $774.00 to $915.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Wolfe Research restated a “peer perform” rating on shares of argenex in a research report on Monday, November 24th. Zacks Research lowered shares of argenex from a “hold” rating to a “strong sell” rating in a research note on Thursday. Finally, Evercore ISI boosted their target price on argenex from $775.00 to $910.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $986.78.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.